Mode
Text Size
Log in / Sign up

Percutaneous Coronary Intervention

Part of Coronary Artery Disease

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Percutaneous Coronary Intervention

15 trials tracked for Percutaneous Coronary Intervention: 7 in phase 3 or 4 and 4 with published results. The most-cited published study has 153 citations.

15Trials tracked
7Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 3 Phase 3 4 Phase 2 1 Other / NA 7
  1. Phase 4 Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI Completed · 153 cited
  2. Phase 3 A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention Completed · 67 cited
  3. Phase 3 Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI) Completed · 26 cited
  4. Phase 4 Adenosine Contrast CorrELations in Evaluating RevAscularizaTION Completed
  5. Phase 4 Chewed Versus Integral Pill of Ticagrelor Completed
  6. Phase 3 A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX) Completed
Show 9 more trials
  1. Phase 3 Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) Completed
  2. Phase 2 Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56 Completed
  3. N/A Efficacy of Long Term Plavix Therapy Post Angioplasty Completed
  4. N/A Improving Cardiac Rehabilitation Outcomes Through Mobile Case Management (iCARE) Completed
  5. N/A Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure Completed
  6. N/A Cardiac Rehabilitation Peer Mentorship Completed
  7. N/A RAVE: Radial Artery Vascular Complication and Resource Utilization Completed
  8. N/A A Smartphone-based Application Post-myocardial Infarction to Manage Cardiovascular Disease Risk Completed
  9. N/A GRX With ReMOTE: First in Human in India Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Percutaneous Coronary Intervention: what the trials found

Clinical trials have evaluated various pharmacological agents and interventions in the context of Percutaneous Coronary Intervention. Cangrelor was shown to significantly impact platelet reactivity as measured by VerifyNow PRU (63; 214, p<0.001) 2. Other established investigations included studies on Iopamidol 3, Ticagrelor [4, 7], and the P2Y12 inhibitor cangrelor 8.

Regarding anticoagulation and bleeding risks, rivaroxaban 2.5 mg was evaluated for clinically significant bleeding (15.7; 16.6; 24.0, p<0.001), while TIMI major and minor bleeding rates did not show statistically significant differences across groups (p=0.234 and p=0.144, respectively) 5. Dabigatran Etexilate 110mg was also studied, showing no significant difference in the time to death of undetermined cause or non-cardiovascular causes 6.

Recent results — preliminary, needs further review

  • Center-Based Cardiac Rehab is currently being evaluated as a new intervention 1.
  • Clopidogrel (not yet corroborated) 9
  • Wellframe (not yet corroborated) 10
  • RadAR EasyCLik plus ®-STF hemostatic pad (not yet corroborated) 11
  • Axiostat® (not yet corroborated) 12

For the clinician treating this condition

  • Cangrelor significantly affects platelet reactivity in patients undergoing intervention 2.
  • Rivaroxaban 2.5 mg is associated with clinically significant bleeding, though TIMI major and minor bleeding rates were not statistically different across cohorts 5.
  • Dabigatran Etexilate 110mg did not show significant differences in time to death of undetermined cause or non-cardiovascular causes 6.

AI synthesis of 10 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Coronary Artery Disease

Related studies from across the Coronary Artery Disease family.

Angiography-derived FFR shows no significant difference in MACE compared to wire-based FFR
Cardiology Meta-analysis
Angiography-derived FFR shows no significant difference in MACE compared to wire-based FFR Angiography-derived FFR Shows No Difference in Major Heart Events
This meta-analysis of 6,542 patients undergoing coronary revascularization found no significant difference in MACE between angiography-deriv…
A review of 6,542 patients shows that angiography-derived FFR does not change major heart outcomes compared to wire-based FFR.
Antiplatelet monotherapy after ultrashort DAPT shows no statistically significant difference in major bleeding or MACE
Cardiology Meta-analysis
Antiplatelet monotherapy after ultrashort DAPT shows no statistically significant difference in major bleeding or MACE Trial Shows Antiplatelet Monotherapy Options for Coronary Artery Disease
This network meta-analysis evaluated antiplatelet monotherapy following an ultrashort course of dual antiplatelet therapy (DAPT) in patients…
New analysis looks at whether switching to a single antiplatelet drug after a short dual therapy period reduces bleeding risks for heart pat…
Sirolimus-coated balloons match paclitaxel-coated balloons for late lumen loss in coronary artery disease
Cardiology Meta-analysis
Sirolimus-coated balloons match paclitaxel-coated balloons for late lumen loss in coronary artery disease Two Drug-Coated Balloons Go Head-to-Head in Heart Artery Treatment
This meta-analysis compared sirolimus-coated balloons with paclitaxel-coated balloons in patients with coronary artery disease. No significa…
A new analysis compares two drug-coated balloons for heart arteries. One may keep vessels open better, but the difference is small.
mAFP support associated with lower odds of mortality in isolated LM culprit lesion
Cardiology RCT
mAFP support associated with lower odds of mortality in isolated LM culprit lesion Heart surgery complexity predicts survival for patients in cardiogenic shock
This RCT substudy of 355 patients with infarct-related cardiogenic shock and multivessel disease found that mAFP support was associated with…
A new analysis shows that the complexity of a patient's heart disease significantly impacts their survival after a heart attack.
Systematic screening for silent myocardial ischemia does not reduce major cardiovascular outcomes in asymptomatic diabetic patients
Cardiology Meta-analysis
Systematic screening for silent myocardial ischemia does not reduce major cardiovascular outcomes in asymptomatic diabetic patients Screening Diabetics for Hidden Heart Disease Does Not Save Lives
This meta-analysis of randomized trials evaluated the impact of systematic screening for silent myocardial ischemia or occult coronary arter…
Screening people with diabetes for hidden heart disease did not reduce heart attacks, strokes, or deaths, a new analysis finds.
Circulating microRNAs show moderate diagnostic accuracy for coronary artery disease, multi-miRNA panels outperform single markers
Cardiology Meta-analysis
Circulating microRNAs show moderate diagnostic accuracy for coronary artery disease, multi-miRNA panels outperform single markers Blood markers show promise for spotting heart artery disease
This meta-analysis of 3879 patients with angiography-confirmed coronary artery disease evaluated circulating microRNAs as diagnostic biomark…
A blood test for tiny molecules called microRNAs may help detect coronary artery disease, a new analysis finds.
AI-enhanced CCTA shows 0.823 sensitivity for detecting hemodynamically significant coronary artery disease
Cardiology Meta-analysis
AI-enhanced CCTA shows 0.823 sensitivity for detecting hemodynamically significant coronary artery disease AI technology improves accuracy in detecting coronary artery disease
This meta-analysis of approximately 8400 patients with suspected coronary artery disease evaluated AI-enhanced coronary CT angiography (CCTA…
New data shows that artificial intelligence can help doctors more accurately identify significant heart disease using noninvasive imaging te…
Cutting balloon predilatation shows lower acute recoil and stenosis compared to standard balloon
Cardiology RCT
Cutting balloon predilatation shows lower acute recoil and stenosis compared to standard balloon Cutting Balloons May Improve Vessel Opening in Heart Procedures
This randomized trial of 201 patients with de novo coronary lesions found that cutting balloon predilatation resulted in lower acute recoil …
A trial of 201 patients with coronary artery disease shows cutting balloons may lead to less vessel recoil during heart procedures.
80 kV CTCA with DLIR maintains image quality while reducing radiation dose by 54-56%
Cardiology Meta-analysis
80 kV CTCA with DLIR maintains image quality while reducing radiation dose by 54-56% Lower Voltage CT Scans May Reduce Radiation for Heart Patients
This meta-analysis of 353 patients evaluates low-dose, low-contrast CTCA using 80 kV and 100 kV with iterative or deep learning image recons…
New data suggests using 80 kV instead of 100 kV during heart scans can significantly lower radiation dose while maintaining image quality.
Comparative Outcomes of Robotic Versus Traditional Coronary Artery Bypass Grafting Procedures
Cardiology Meta-analysis
Comparative Outcomes of Robotic Versus Traditional Coronary Artery Bypass Grafting Procedures Robotic Surgery Shows Similar Outcomes to Traditional Heart Bypass Surgery
A meta-analysis of 27 studies indicates that robotic-assisted techniques provide comparable graft patency and mortality rates compared to tr…
Robotic-assisted heart bypass surgery shows similar survival rates and graft success compared to traditional methods for patients with coron…
T-786C polymorphism of the NOS3 gene is associated with increased risk of acute coronary syndrome
Cardiology Meta-analysis
T-786C polymorphism of the NOS3 gene is associated with increased risk of acute coronary syndrome Genetic Variation Linked to Increased Risk of Heart Disease
This meta-analysis of 17,324 subjects found a significant association between the T-786C polymorphism of the nitric oxide synthase 3 (NOS3) …
A specific genetic variation in the NOS3 gene is linked to a higher risk of heart conditions like coronary artery disease and heart attacks.
One-stent technique and OCT-guided DK-crush associated with lower major adverse cardiac events
Radiology & Imaging RCT
One-stent technique and OCT-guided DK-crush associated with lower major adverse cardiac events Trial shows single stent technique may lower heart risks
This post hoc analysis of patients with coronary artery disease evaluated outcomes based on stenting techniques and guidance methods for DK-…
A new analysis of heart procedures suggests that using one stent instead of two may reduce serious complications for patients with complex a…

Questions about Percutaneous Coronary Intervention

Can an AI model help doctors decide on my treatment plan for Percutaneous Coronary Intervention?

AI models are not yet proven to help doctors decide on PCI treatment plans; current research focuses on imaging and risk scores, not AI decision support.

Full answer →
Does a higher dose of heparin during elective PCI reduce bleeding complications?

Current evidence does not show that a higher heparin dose reduces bleeding; lower doses may be safer, but definitive results from the HD-PCI trial are pending.

Full answer →
Will stopping aspirin early after my Percutaneous Coronary Intervention cause a heart attack?

Stopping aspirin early after PCI may increase heart attack risk if no other antiplatelet is used, but switching to a P2Y12 inhibitor alone within 3 months does not significantly raise MI risk and reduces bleeding.

Full answer →
Can using intravascular imaging reduce my risk of major adverse events after PCI?

Yes, using intravascular imaging (IVUS or OCT) to guide PCI significantly reduces the risk of major adverse cardiovascular events compared to angiography alone.

Full answer →
Does having metabolic syndrome increase my risk of restenosis after Percutaneous Coronary Intervention?

Current evidence does not show a clear link between metabolic syndrome and higher restenosis risk after PCI, though related factors like insulin resistance may play a role.

Full answer →
See all 5 questions about Percutaneous Coronary Intervention →